ESTRO 2025 - Abstract Book

S2083

Clinical - Urology

ESTRO 2025

Conclusion: Proton-based reRT for PCa demonstrates a good acute toxicity profile. The precise dosimetric capabilities of proton therapy allows for effective tumor control while sparing OARs, making it a viable option for reRT.

Keywords: reirradiation, proton therapy, prostate

3961

Poster Discussion Acute toxicity of early salvage radiotherapy in 5 fractions for post-prostatectomy biochemical failure Marta Bottero 1 , Adriana Faiella 2 , Alessia Farneti 2 , Alessandro Magli 3 , Elisa Villa 4 , Enrico Raggi 5 , Giuseppe Sanguineti 2 1 Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome,, Italy. 2 Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 3 Radiation Oncology, ASUGI, Trieste, Italy. 4 Radiation Oncology, Humanitas Gavazzeni, Bergamo, Italy. 5 Radiation Oncology, AULSS1, Belluno, Italy Purpose/Objective: To assess acute toxicity in prostate cancer patients treated with post-prostatectomy (P) salvage stereotactic radiotherapy (SBRT). Material/Methods: This multicenter prospective phase II study enrolled patients with biochemical recurrence (BCR) after P. Eligible patients had prostate-specific antigen (PSA) between 0.2 and 2 ng/mL, no pathological lymphnodes at P, no evidence of nodal/distant disease on restaging positron emission tomography/prostate-specific membrane antigen.